Travere Therapeutics (TVTX) Could Be 28% Undervalued As FILSPARI Data And Patent Land

Clinical and Patent News Around Travere Therapeutics

Travere Therapeutics (TVTX) has become a talking point after new FILSPARI data and fresh patent protection through 2037 put its rare kidney disease franchise in sharper focus for investors.

Recent trading has been choppy for Travere Therapeutics, with the share price down 18.14% over the past month and 8.60% over 90 days, even as year to date share price return is 35.22% and the 1-year total shareholder return is 103.97%. The contrast between the weaker near term share price and the very large 3-year total shareholder return of about 7x suggests that investors are reassessing how much of FILSPARI’s clinical and patent news is already reflected in the current US$53.44 price, and how much future kidney franchise risk or opportunity they want to price in now.

Capture how Travere Therapeutics fits into the rare disease opportunity set by scanning a curated list of 20 high quality undiscovered gems with similarly focused fundamentals and specialist pipelines.

Travere Therapeutics now has stronger clinical evidence and fresh patent cover, yet the share price has pulled back sharply in recent weeks. Is this still a quality rare disease story at a fair price today?

Most Popular Narrative: 28% Undervalued

Travere Therapeutics last closed at $53.44, while the most followed narrative pegs fair value at about $74.14. This frames the recent pullback as a potential disconnect between price and the rare kidney thesis.

Travere's strengthening financial position driven by rapid product sales growth, increased international out-licensing revenues, significant reductions in net losses, and prudent R&D and SG&A management sets a foundation for positive net earnings, while securing resources for continued pipeline development and future commercial launches.

See why 22 investors see Travere Therapeutics as 28% undervalued.

Result: Fair Value of $74.14 (UNDERVALUED)

Still, the Travere Therapeutics story leans heavily on FILSPARI, so any regulatory setback or slower than modeled adoption could quickly challenge that 28% undervalued narrative.

Find out about the key risks to this Travere Therapeutics narrative.

Next Steps

Confident about the rare kidney story so far, or still on the fence about Travere Therapeutics after the recent volatility and mixed signals? Pressure test that optimism by reviewing the 4 key rewards.

Looking For More Ideas Beyond Travere Therapeutics?

Do not stop your research with Travere Therapeutics, because the next opportunity you appreciate most could be sitting in plain sight on a targeted screener.

• Target dependable paychecks from your portfolio by reviewing a curated field of income stocks as a starting point with the 8 dividend fortresses.
• Hunt for quality at a price that still leaves room for upside by working through the fundamentals focused set in the 29 high quality undervalued stocks.
• Prioritise sleep at night potential and stress test your downside tolerance by filtering candidates in the 31 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com